Why TransCode Therapeutics (RNAZ) Shares Are Trading Higher Today

  • TransCode Therapeutics Inc RNAZ reported preclinical proof-of-mechanism studies with its immunotherapy candidate, TTX-RIGA, in melanoma.
  • TTX-RIGA, a novel immunotherapeutic cancer candidate, is designed to work by binding to an intracellular receptor called RIG-I (retinoic acid-inducible gene I), expected to result in targeted activation of innate immunity in the tumor microenvironment
  • In preclinical studies, TransCode's delivery of TTX-RIGA inside tumors and metastases generated an RNA-based agonist of the RIG-I gene, targeting the activation of innate immunity in the tumor microenvironment in multiple solid tumors.
  • "As with prior studies, we believe the data from this preclinical study further support the advancement of TTX-RIGA into animal studies slated to begin in February 2023," commented Zdravka Medarova, co-founder & CTO of TransCode. 
  • "We believe that demonstrating successful preclinical results with TTX-RIGA is an important step in the preclinical development process and further de-risks our pipeline that includes multiple RNA approaches," added Michael Dudley, co-founder, president, and CEO of TransCode.
  • Dudley added, "we received written authorization from the FDA to proceed with our Phase 0 first-in-human (FIH) clinical trial with our lead candidate, TTX-MC138, in cancer patients with advanced solid tumors. We intend to proceed with patient enrollment as soon as possible."
  • Price Action: RNAZ shares are up 43.90% at $1.08 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CarePre-Market OutlookMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!